Difficult (for me anyway) to pin down a long term target. Depends on terms of any initial licensing deal (how much we give away) for funding, from there we might be able to extrapolate over the product line adjusted for market size to derive some sort of value for ANP, But its not my area of expertise.
Doesnt take much to realise that the current MC provides significant upside potential over different scenarios.
Aces, Teefer et al would have a better idea that me.
All IMHO only
Good luck to holders
- Forums
- ASX - By Stock
- PER
- deja vu
deja vu, page-6
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $85.01M |
Open | High | Low | Value | Volume |
8.5¢ | 8.6¢ | 8.2¢ | $103.7K | 1.237M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 204084 | 8.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.5¢ | 280000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 204084 | 0.082 |
3 | 287000 | 0.081 |
8 | 672686 | 0.080 |
6 | 413817 | 0.079 |
6 | 689399 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.085 | 280000 | 3 |
0.086 | 96543 | 1 |
0.088 | 27962 | 1 |
0.089 | 200000 | 1 |
0.090 | 604764 | 4 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online